Candel Therapeutics (CADL) Competitors $5.56 -0.40 (-6.71%) Closing price 04:00 PM EasternExtended Trading$5.70 +0.14 (+2.43%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CADL vs. CALT, PAHC, NTLA, AMPH, XERS, COLL, SNDX, PHVS, VERV, and LENZShould you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Intellia Therapeutics (NTLA), Amphastar Pharmaceuticals (AMPH), Xeris Biopharma (XERS), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Pharvaris (PHVS), Verve Therapeutics (VERV), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. Candel Therapeutics vs. Its Competitors Calliditas Therapeutics AB (publ) Phibro Animal Health Intellia Therapeutics Amphastar Pharmaceuticals Xeris Biopharma Collegium Pharmaceutical Syndax Pharmaceuticals Pharvaris Verve Therapeutics LENZ Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability. Do institutionals and insiders hold more shares of CALT or CADL? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 16.6% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, CALT or CADL? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Candel Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Candel Therapeutics$120K2,543.70-$55.18M-$0.69-8.06 Do analysts recommend CALT or CADL? Candel Therapeutics has a consensus price target of $22.00, suggesting a potential upside of 295.68%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Candel Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Is CALT or CADL more profitable? Candel Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Candel Therapeutics' return on equity of -52.81% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Candel Therapeutics N/A -52.81%-29.61% Which has more volatility and risk, CALT or CADL? Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.88, suggesting that its stock price is 188% less volatile than the S&P 500. Does the media prefer CALT or CADL? In the previous week, Candel Therapeutics had 9 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 10 mentions for Candel Therapeutics and 1 mentions for Calliditas Therapeutics AB (publ). Candel Therapeutics' average media sentiment score of 0.53 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Calliditas Therapeutics AB (publ) 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Candel Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive SummaryCandel Therapeutics beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks. Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CADL vs. The Competition Export to ExcelMetricCandel TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$305.24M$3.07B$5.76B$9.65BDividend YieldN/A2.22%3.91%4.09%P/E Ratio-8.0620.4830.7825.12Price / Sales2,543.70355.18456.64116.46Price / CashN/A41.5625.2228.45Price / Book3.949.549.375.95Net Income-$55.18M-$54.74M$3.26B$265.46M7 Day Performance-12.44%2.39%1.88%0.96%1 Month Performance-17.51%4.60%3.73%2.47%1 Year Performance5.90%9.17%28.93%20.24% Candel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CADLCandel Therapeutics2.7587 of 5 stars$5.56-6.7%$22.00+295.7%+13.1%$305.24M$120K-8.0660Earnings ReportCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health3.5623 of 5 stars$28.54+1.6%$24.40-14.5%+73.1%$1.14B$1.02B36.591,940Positive NewsNTLAIntellia Therapeutics4.4474 of 5 stars$10.74-0.5%$30.68+185.7%-52.6%$1.12B$57.88M-2.29600AMPHAmphastar Pharmaceuticals3.2012 of 5 stars$27.36+14.9%$30.00+9.6%-33.8%$1.11B$731.97M10.252,028High Trading VolumeXERSXeris Biopharma3.4026 of 5 stars$7.20+5.3%$6.25-13.2%+173.6%$1.10B$203.07M-34.28290COLLCollegium Pharmaceutical2.9368 of 5 stars$36.14+3.5%$42.33+17.1%+8.3%$1.10B$631.45M34.75210SNDXSyndax Pharmaceuticals4.0456 of 5 stars$12.51+0.2%$36.91+195.0%-20.4%$1.08B$23.68M-3.22110News CoverageInsider TradePHVSPharvaris2.7415 of 5 stars$20.84+3.6%$36.20+73.7%+18.2%$1.05BN/A-6.9230Earnings ReportShort Interest ↓Analyst RevisionVERVVerve Therapeutics3.0718 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110LENZLENZ Therapeutics2.0326 of 5 stars$38.77+11.8%$49.60+27.9%+70.4%$989.15MN/A-20.41110Gap UpHigh Trading Volume Related Companies and Tools Related Companies CALT Competitors PAHC Competitors NTLA Competitors AMPH Competitors XERS Competitors COLL Competitors SNDX Competitors PHVS Competitors VERV Competitors LENZ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CADL) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access